Eintrag weiter verarbeiten
CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , |
| In: | Journal of Clinical Oncology, 25, 2007, 18_suppl, S. 8081-8081 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| Zusammenfassung: | <jats:p> 8081 </jats:p><jats:p> Background: THP-ADM (Pirarubicin) has potential to replace conventional ADM (Adriamycin) because of less severe toxicities. However, only a few studies have compared the long-term outcome between patients receiving the two drugs. A Japanese trial (JGTLE) shows the CR rate of THP-COP group was greater than CHOP group in elderly T-cell Non-Hodgkin's Lymphoma (NHL) patients. The current study was aimed at comparing the long-term outcome and toxicities between NHL patients receiving CHOP and THP-COP regimens within similar age-groups and pathological sub-types. Methods: 505 previously untreated NHL patients receiving either standard CHOP or THP-COP regimen (cyclophosphamide 750 mg/m<jats:sup>2</jats:sup>, doxorubicin or pirarubicin 50 mg/m<jats:sup>2</jats:sup>, vincristine 1.4 mg/m<jats:sup>2</jats:sup>and prednisone 40 mg/m<jats:sup>2</jats:sup> for 5 days) were enrolled. Results: Patients’ characteristics between CHOP group(n=279) and THP-COP (n=228) group were well balanced. There were no differences in CR rate (54.8% vs. 54.0%, p=0.85) and response rate (82.1% vs. 84.1%, p=0.55). With a median follow-up of 59.7months, survival rate was similar (5-year OS: 56.7% vs. 55.8%, 5-year PFS: 43.5% vs. 47.3%, 5-year DFS: 54.0% vs. 54.7%). The incidence of cardiotoxicity(myocardial dysfunction and arrhythmia)was almost the same (10.0% vs10.2 %; P=0.958). Less Alopecia (39.1% vs. 28.8%, p= 0.015)and gastrointestinal toxicities(63.1% vs. 50.0%, p=0.003) were observed in THP-COP group. No differences between the two groups were observed within different pathological subtypes (B-cell subtype: CR rate 58.2% vs. 56.7%, 5-year OS 59.2% vs. 60.0%; T-cell subtype: CR rate 47.0% vs. 45.5%, 5-year OS 50.5% vs. 43.4%) and age-groups (<60 years group: CR rate 51.6% vs. 53.7%, p= 0.684; 5y OS 58.9% vs.61.1%, p= 0.570; =60 years group: CR rate 67.9% vs. 54.8 %, p= 0.148; 5y OS 48.0% vs. 42.1 %, p= 0.314). In the 33 elderly patients of T-cell subtype, CR rates were almost the same. (73.7% vs. 42.9%, p=0.073). Conclusions: The long-term outcome of NHL patients receiving THP-COP is similar to those receiving CHOP within similar age groups and pathologic subtypes. Cardiotoxicity occurs at a similar rate in both groups, while a lower incidence of alopecia and gastrointestinal toxicities was observed in THP-COP group. </jats:p><jats:p> No significant financial relationships to disclose. </jats:p> |
|---|---|
| Umfang: | 8081-8081 |
| ISSN: |
1527-7755
0732-183X |
| DOI: | 10.1200/jco.2007.25.18_suppl.8081 |